Korea Research Institute of Bioscience and Biotechnology

Sungkyunkwan University

So-Young Choi

Young Woo Park

Jung Jae Yu

Ji Hyun Park

Myeoung Hee Jang

Joon-Goo Jung

Sungsub Kim

Eun-Jung Song

Myung-ho Sohn

Jae Won Jeon

Jong-Ho Park

Hyo Jeong Hong

Jeong Ho Yoon

Semi Kim

Mi-ju Park

Je-Ho Lee

Jae Ryoung Hwang

Kiwon Jo

Young-Soon Jang

Young-soon Jang

Kwang Pyo Lee

So Jeong Park

Heekyung Jung

Mi-Ju Park

The present invention relates to an anticancer agent containing a TMPRSS4 (transmembrane protease, serine 4) inhibitor as an effective ingredient, more precisely an anticancer agent containing an inhibitor of TMPRSS4 activity as an effective ingredient. The anticancer agent of the present invention can be used effectively for the treatment of cancer by inhibiting TMPRSS4 expression in cancer cells and thereby inhibiting cancer cell invasion and cancer cell growth.

Anticancer drug comprising inhibitor of TMPRSS4

The present invention relates to a transmembrane protease, serine (TMPRSS4)-specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to TMPRSS4. The TMPRSS4-specific human antibody expressed in the various kinds of cancer cells of the present invention may be used in diagnosis of the cancer, classification of the disease, visualization, treatment, and prognostic evaluation.

TMPRSS4-specific human antibody

The present invention relates to a vascular endothelial growth factor (VEGF)-specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to VEGF. The VEGF-specific human antibody of the present invention may be used in diagnosis of diseases caused by the VEGF-overexpression, classification of the diseases, visualization, treatment, and prognostic evaluation.

VEGF-specific human antibody

The present invention relates to a CD9-specific human antibody, more precisely a CD9-specific human antibody composed of human derived CD9-specific complementarity determining region (CDR) and framework region (FR). The human antibody of the present invention recognizes CD9 extracellular loop 2 domain (CD9-ECL2) as an epitope and thereby strongly binding thereto. The human antibody of the present invention also has CD9 antigen neutralizing effect and at the same time inhibiting effect on tumor cell lines. Therefore, it can be effectively used for the prevention and treatment of cancer overexpressing CD9.

CD9-specific human antibodies

Growing community of inventors

Daejeon, South Korea

So-Young Choi